Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $33.5 million.

  • Arrowhead Pharmaceuticals' Change in Accured Expenses rose 76.24% to $33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 29.21%. This contributed to the annual value of $41.5 million for FY2025, which is 29.21% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Change in Accured Expenses stood at $33.5 million, which was up 405.89% from -$11.0 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $33.5 million during Q3 2025, with a 5-year trough of -$20.1 million in Q1 2023.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Change in Accured Expenses value was $408,000 (recorded in 2023), while the average stood at $6.0 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Change in Accured Expenses tumbled by 1,985.05% in 2024 and then spiked by 6,451.31% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at -$2.3 million in 2021, then tumbled by 214.54% to -$7.2 million in 2022, then skyrocketed by 105.66% to $408,000 in 2023, then plummeted by 1,985.05% to -$7.7 million in 2024, then spiked by 76.24% to $33.5 million in 2025.
  • Its last three reported values are $33.5 million in Q3 2025, -$11.0 million for Q2 2025, and $26.6 million during Q1 2025.